Docoh
Loading...

SERA Sera Prognostics

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to deliver early, pivotal information in pregnancy to physicians, enabling them to improve the health of their patients, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is located in Salt Lake City, Utah.

SERA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

30 Aug 21
22 Oct 21
31 Dec 21
Quarter (USD)
Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 90.85M 90.85M
Cash burn (monthly) 2.46M 283.33K
Cash used (since last report) 9.21M 1.06M
Cash remaining 81.64M 89.79M
Runway (months of cash) 33.2 316.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Aug 21 Thomas Garite Stock Option Class A Common Stock Grant Acquire A No No 9.95 10,000 99.5K 10,000
19 Jul 21 Blue Ox Healthcare Partners Class A Common Stock Conversion Acquire C Yes No 0 1,204,508 0 1,204,508
19 Jul 21 Blue Ox Healthcare Partners Class A Common Stock Conversion Acquire C Yes No 0 1,075,047 0 1,075,047
19 Jul 21 Blue Ox Healthcare Partners Class A Common Stock Conversion Acquire C Yes No 0 1,515,595 0 1,515,595
19 Jul 21 Blue Ox Healthcare Partners Series E Convertible Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 1,204,508 0 0
19 Jul 21 Blue Ox Healthcare Partners Series D Convertible Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 1,075,047 0 0
19 Jul 21 Blue Ox Healthcare Partners Series D Convertible Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 1,515,595 0 0
19 Jul 21 Joshua Phillips Class A Common Stock Conversion Acquire C Yes No 0 3,713 0 965,111
19 Jul 21 Joshua Phillips Class A Common Stock Conversion Acquire C Yes No 0 32,335 0 961,398
19 Jul 21 Joshua Phillips Class A Common Stock Conversion Acquire C Yes No 0 160,601 0 929,063

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • We cannot ensure that our employees will fully adhere to compliance policies and procedures.
  • We may be adversely impacted by changes in laws and regulations, or in their application.
  • Our intellectual property may be infringed upon by a third party.
  • The price of our Class A common stock may be volatile, and you could lose all or part of your investment.*
  • The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.*
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.*
Management Discussion
  • The results of operations presented below should be reviewed in conjunction with the condensed financial statements and related notes included elsewhere in this report.
  • The $1.1 million increase was due to a $0.5 million increase in laboratory operations costs, a $0.3 million increase in clinical study costs and a $0.2 million increase in research and bioinformatics expenses. The $0.5 million increase in laboratory operations costs is primarily due to a $0.2 million increase in stock-based compensation expense resulting from equity grants in the first quarter of 2021, a $0.2 million increase in lab supplies and a $0.1 million increase in personnel costs driven by increased headcount. The $0.3 million increase in clinical study costs is primarily due to the
  • increased enrollment and site setup activity in the PRIME study. The $0.2 million increase in research and bioinformatics expenses was due to personnel costs primarily driven by increased headcount.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg

Proxies

No filings

Patents

APP
Utility
Biomarkers for Predicting Preterm Birth Due to Preterm Premature Rupture of Membranes (Pprom) Versus Idiopathic Spontaneous Labor (PTL)
24 Jun 21
The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female.
APP
Utility
Biomarker Pairs for Predicting Preterm Birth
17 Jun 21
The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
APP
Utility
Biomarkers and Methods for Predicting Preeclampsia
27 May 21
The disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female.
GRANT
Utility
Biomarker pairs for predicting preterm birth
30 Mar 21
The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.
APP
Utility
Biomarker Pairs for Predicting Preterm Birth
4 Mar 20
The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.